Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
$1,318.00
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 89,000 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.
- Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
- The majority of industry-sponsored drugs in active clinical development for ALL are in Phase II, with only one drug in Phase III. Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being tested as oral formulations.
- High-impact upcoming events for drugs in the ALL space comprise topline Phase II trial results for Sarclisa, and an expected CHMP opinion as well as an estimated European approval decision for Rylaze.
- The overall likelihood of approval of a Phase I hematologic asset is 7.7%, and the average probability a drug advances from Phase III is 55.9%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.9 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of ALL clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Novartis has the highest number of completed clinical trials for ALL, with 44 trials. Novartis also leads industry sponsors with the highest overall number of clinical trials for ALL.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Chemotherapy
11 Corticosteroids
11 TKI therapy
11 Immunotherapy
12 Radiation therapy
12 Stem cell transplant
13 EPIDEMIOLOGY
16 MARKETED DRUGS
21 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 Darzalex for ALL (June 6, 2022)
30 Tecartus for ALL (June 4, 2021)
32 Tecartus for ALL (May 19, 2021)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Kite Wins EMA Recommendation To Market Tecartus For Leukemia Patients
35 Jazz Pharmaceuticals’ Crisantaspase Among New Filings At EMA
35 New RMAT Designations Include Autolus’s CAR-T
36 Accord Receives CHMP Endorsements For Dasatinib
36 Xspray Pharma’s Dasynoc Under FDA Review
36 First Academic Sponsor On EMA’s PRIME Pledges Cheaper CAR-Ts
37 US FDA Cancels Panel Review Of Two ‘Delinquent’ Cancer Drug Accelerated Approvals
38 PROBABILITY OF SUCCESS
39 LICENSING AND ASSET ACQUISITION DEALS
39 Catalent Announces Exclusive Long-Term Supply Agreement With Erytech
39 Laurus Labs Buys Into Indian CAR-T Start-Up
39 Autolus On The Rise After Big Backing From Blackstone
41 REVENUE OPPORTUNITY
43 CLINICAL TRIAL LANDSCAPE
44 Sponsors by status
45 Sponsors by phase
46 Recent events
48 BIBLIOGRAPHY
50 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of ALL, 2018–27
21 Figure 2: Overview of pipeline drugs for ALL in the US
21 Figure 3: Pipeline drugs for ALL, by company
22 Figure 4: Pipeline drugs for ALL, by drug type
22 Figure 5: Pipeline drugs for ALL, by classification
32 Figure 6: Tecartus for ALL (June 4, 2021): Phase I/II – ZUMA-3 (r/r Adults)
34 Figure 7: Key upcoming events in ALL
38 Figure 8: Probability of success in the hematologic pipeline
43 Figure 9: Clinical trials in ALL
43 Figure 10: Top 10 drugs for clinical trials in ALL
44 Figure 11: Top 10 companies for clinical trials in ALL
44 Figure 12: Trial locations in ALL
45 Figure 13: ALL trials status
46 Figure 14: ALL trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of ALL, 2018–27
17 Table 2: Marketed drugs for ALL
23 Table 3: Pipeline drugs for ALL in the US
29 Table 4: Darzalex for ALL (June 6, 2022)
30 Table 5: Tecartus for ALL (June 4, 2021)
33 Table 6: Tecartus for ALL (May 19, 2021)
41 Table 7: Historical global sales, by drug ($m), 2017–21
42 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Diabetic Nephropathy 
Sign up to the